scholarly journals Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn’s disease: analysis from the PRACTICROHN study

2019 ◽  
Vol 7 (3) ◽  
pp. 168-175 ◽  
Author(s):  
Ana Gutiérrez ◽  
Montserrat Rivero ◽  
Maria Dolores Martín-Arranz ◽  
Valle García Sánchez ◽  
Manuel Castro ◽  
...  
Author(s):  
Evelien M.J. Beelen ◽  
Annemarie C. de Vries ◽  
Alexander G. Bodelier ◽  
Jolyn Moolenaar ◽  
W. Rudolph Schouten ◽  
...  

2021 ◽  
Vol 160 (6) ◽  
pp. S-4
Author(s):  
Andres Yarur ◽  
Brian Bressler ◽  
Song Wang ◽  
Shashi Adsul ◽  
Pravin Kamble ◽  
...  

2003 ◽  
Vol 17 (1) ◽  
pp. 43-46 ◽  
Author(s):  
Hugh J Freeman

Earlier investigations demonstrate an increased risk for colon cancer in Crohn's disease. For other intestinal neoplasms, such as carcinoids, studies are limited. In Crohn's disease, repeated endoscopic and imaging studies along with intestinal resections may facilitate clinical recognition of neoplastic diseases, including appendiceal neoplasms. To date, however, only sporadic cases of appendiceal carcinoids have been described in Crohn's disease. In the present study, in a single clinician database of 1000 Crohn's disease patients, three of the 441 patients who had undergone intestinal resection had appendiceal carcinoids, all of which were pathologically confirmed. All were observed in female patients and were not suspected before surgical treatment. In one case, even though management was not altered, the tumour had already invaded serosal fat indicating a potential for more advanced disease. In this series, a carcinoid tumour was found in a resection specimen during a later clinical case review and another was a microcarcinoid, implying that these tumours may be overlooked in Crohn's disease. The percentage detected in the entire database (0.3%) exceeds the reported rates of detection of appendiceal carcinoids after removal of the appendix for appendicitis, as well as the rate of detection of appendiceal carcinoids in autopsy studies. This percentage would be higher if only those having an intestinal resection were considered (0.68%). Additional studies are needed to further define this risk of appendiceal carcinoids in Crohn's disease.


2020 ◽  
Author(s):  
Shahan Mamoor

Inflammatory bowel diseases (IBD) include Crohn’s Disease and Ulcerative Colitis (1). We mined published microarray data to understand how gene expression in the hematopoietic compartment of patients with Crohn’s Disease is most different from that of healthy controls (2-4). Across two datasets (2, 3), we found that BAFF, also known as the B-lymphocyte stimulator (BLyS), encoded by the gene TNFSF13B (5), was differentially expressed in the blood of patients with Crohn’s Disease . Analysis of a third dataset (4) revealed that BAFF was among the genes most differentially expressed in monocyte-derived macrophages from patients with Crohn’s Disease. Serum BAFF, fecal BAFF, and BAFF expression in the intestinal mucosa has been demonstrated to be increased in patients with IBD (6, 7). We show here that expression of BAFF in the peripheral blood of patients with Crohn’s Disease is also increased.


2020 ◽  
Author(s):  
Shahan Mamoor

Crohn’s disease, an inflammatory bowel disease of the gastrointestinal tract (1), causes significant morbidity and nearly 3.5 billion dollars in lost economic productivity in the United States (2) due to complications of the disease. We mined transcriptome and methylome datasets (3, 4) to understand, in an unbiased manner, the most significant changes in gene expression and DNA methylation in the hematopoietic system of patients with Crohn’s disease (CD). We identified the zinc finger and BTB (broad complex, tramtrack, bric-à-brac) domain-containing gene ZBTB6 (5, 6) as one of the most differentially expressed genes in the whole blood of patients with Crohn’s disease. Analysis of a separate data revealed that the ZBTB6 locus was one of the most differentially methylated sites globally in the blood of patients with Crohn’s disease when compared to the blood of healthy patients. ZBTB6 is differentially methylated and differentially expressed in the blood of patients with Crohn’s disease, and more significantly so than the vast majority of the human genome. These data point to inhibition of ZBTB6 gene expression by hyper-methylation of the ZBTB6 locus and suggest that titration of some function or transcriptional target of ZBTB6 may be an important event in the pathogenesis of Crohn’s disease.


2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Evelien M. J. Beelen ◽  
C. Janneke van der Woude ◽  
Marie J. Pierik ◽  
Frank Hoentjen ◽  
Nanne K. de Boer ◽  
...  

2019 ◽  
Vol 25 (Supplement_1) ◽  
pp. S37-S37
Author(s):  
Atsuyo Ikeda ◽  
Norikatsu Miyoshi ◽  
Shiki Fujino ◽  
Hideki Iijima ◽  
Hidekazu Takahashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document